Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  2. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists
  3. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.

  4. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC).

  5. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.

    International brands: My-B-Den
  6. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.

  7. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor … [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

  9. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.

  10. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

    Categories: Endothelin A Receptor Antagonists, Endothelin Receptor Antagonists